Lilly’s weight-loss company orforgliliprone could receive FDA approval in 2026, CEO Dave Ricks says.

Eli Lilly & Co., the Fortune 500 pharmaceutical company that makes weight-loss injection Zepbound (tirzepatide), has a similar oral drug in the works that could be approved by the U.S. Food and Drug Administration as early as 2026, according to CEO Dave Rex told Bloomberg TV in January. 13, 2025.

Gam1983/Getty Images